TY - JOUR
T1 - ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers
AU - Tacconelli, E.
AU - Mazzaferri, F.
AU - de Smet, A. M.
AU - Bragantini, D.
AU - Eggimann, P.
AU - Huttner, B. D.
AU - Kuijper, E. J.
AU - Lucet, J. C.
AU - Mutters, N. T.
AU - Sanguinetti, M.
AU - Schwaber, M. J.
AU - Souli, M.
AU - Torre-Cisneros, J.
AU - Price, J. R.
AU - Rodríguez-Baño, J.
N1 - Funding Information:
ET, FM, AMD, DB, BDH, EJK, JCL, NTM, MJS, Maria Souli, JTC, JRP declared no conflicts of interest. PE has witnessed advisory and consultancy roles at Abionic, 3M, Pfizer, Aridis and received research support from 3M. Maurizio Sanguinetti received research support from Recordatai, Pfizer and Menarini s.p.a. JRB participated in accredited educational activities supported by Merck through unrestricted grants and was coordinator of a drug-unrelated research project funded by AstraZeneca.JTC and JRB are supported by ‘Plan Nacional de I+D+i 2013-2016’ and ‘Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; RD16/0016/0008)’ co-financed by the European Development Regional Fund ‘A way to achieve Europe’ Operative Programme Intelligent Growth 2014-2020.We thank Anne McDonough, a professional medical writer funded by ESCMID, for editorial assistance.
Funding Information:
JTC and JRB are supported by ‘ Plan Nacional de I+D+i 2013-2016 ’ and ‘ Instituto de Salud Carlos III , Subdirección General de Redes y Centros de Investigación Cooperativa , Ministerio de Economía, Industria y Competitividad , Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001 ; RD16/0016/0008 )’, co-financed by the European Development Regional Fund ‘A way to achieve Europe’, Operative Programme Intelligent Growth 2014-2020.
Funding Information:
ET, FM, AMD, DB, BDH, EJK, JCL, NTM, MJS, Maria Souli, JTC, JRP declared no conflicts of interest. PE has witnessed advisory and consultancy roles at Abionic, 3M, Pfizer, Aridis and received research support from 3M. Maurizio Sanguinetti received research support from Recordatai, Pfizer and Menarini s.p.a. JRB participated in accredited educational activities supported by Merck through unrestricted grants and was coordinator of a drug-unrelated research project funded by AstraZeneca.JTC and JRB are supported by ?Plan Nacional de I+D+i 2013-2016? and ?Instituto de Salud Carlos III, Subdirecci?n General de Redes y Centros de Investigaci?n Cooperativa, Ministerio de Econom?a, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; RD16/0016/0008)?, co-financed by the European Development Regional Fund ?A way to achieve Europe?, Operative Programme Intelligent Growth 2014-2020.We thank Anne McDonough, a professional medical writer funded by ESCMID, for editorial assistance. A preliminary version of these guidelines was presented at ECCMID 2018, 21?24 April 2018, Madrid, Spain.
Funding Information:
We thank Anne McDonough, a professional medical writer funded by ESCMID , for editorial assistance.
Publisher Copyright:
© 2019 The Authors
PY - 2019/7
Y1 - 2019/7
N2 - Scope: The aim of these guidelines is to provide recommendations for decolonizing regimens targeting multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings. Methods: These evidence-based guidelines were produced after a systematic review of published studies on decolonization interventions targeting the following MDR-GNB: third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE), aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginosa (XDRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), cotrimoxazole-resistant Stenotrophomonas maltophilia (CRSM), colistin-resistant Gram-negative organisms (CoRGNB), and pan-drug-resistant Gram-negative organisms (PDRGNB). The recommendations are grouped by MDR-GNB species. Faecal microbiota transplantation has been discussed separately. Four types of outcomes were evaluated for each target MDR-GNB:(a) microbiological outcomes (carriage and eradication rates) at treatment end and at specific post-treatment time-points; (b) clinical outcomes (attributable and all-cause mortality and infection incidence) at the same time-points and length of hospital stay; (c) epidemiological outcomes (acquisition incidence, transmission and outbreaks); and (d) adverse events of decolonization (including resistance development). The level of evidence for and strength of each recommendation were defined according to the GRADE approach. Consensus of a multidisciplinary expert panel was reached through a nominal-group technique for the final list of recommendations. Recommendations: The panel does not recommend routine decolonization of 3GCephRE and CRE carriers. Evidence is currently insufficient to provide recommendations for or against any intervention in patients colonized with AGRE, CoRGNB, CRAB, CRSM, FQRE, PDRGNB and XDRPA. On the basis of the limited evidence of increased risk of CRE infections in immunocompromised carriers, the panel suggests designing high-quality prospective clinical studies to assess the risk of CRE infections in immunocompromised patients. These trials should include monitoring of development of resistance to decolonizing agents during treatment using stool cultures and antimicrobial susceptibility results according to the EUCAST clinical breakpoints.
AB - Scope: The aim of these guidelines is to provide recommendations for decolonizing regimens targeting multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings. Methods: These evidence-based guidelines were produced after a systematic review of published studies on decolonization interventions targeting the following MDR-GNB: third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE), aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginosa (XDRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), cotrimoxazole-resistant Stenotrophomonas maltophilia (CRSM), colistin-resistant Gram-negative organisms (CoRGNB), and pan-drug-resistant Gram-negative organisms (PDRGNB). The recommendations are grouped by MDR-GNB species. Faecal microbiota transplantation has been discussed separately. Four types of outcomes were evaluated for each target MDR-GNB:(a) microbiological outcomes (carriage and eradication rates) at treatment end and at specific post-treatment time-points; (b) clinical outcomes (attributable and all-cause mortality and infection incidence) at the same time-points and length of hospital stay; (c) epidemiological outcomes (acquisition incidence, transmission and outbreaks); and (d) adverse events of decolonization (including resistance development). The level of evidence for and strength of each recommendation were defined according to the GRADE approach. Consensus of a multidisciplinary expert panel was reached through a nominal-group technique for the final list of recommendations. Recommendations: The panel does not recommend routine decolonization of 3GCephRE and CRE carriers. Evidence is currently insufficient to provide recommendations for or against any intervention in patients colonized with AGRE, CoRGNB, CRAB, CRSM, FQRE, PDRGNB and XDRPA. On the basis of the limited evidence of increased risk of CRE infections in immunocompromised carriers, the panel suggests designing high-quality prospective clinical studies to assess the risk of CRE infections in immunocompromised patients. These trials should include monitoring of development of resistance to decolonizing agents during treatment using stool cultures and antimicrobial susceptibility results according to the EUCAST clinical breakpoints.
KW - Acinetobacter
KW - Carbapenemase
KW - Decolonization
KW - Enterobacteriaceae
KW - Extended-spectrum β-lactamase
KW - Guideline
KW - Multidrug-resistant Gram-negative
KW - Pseudomonas
KW - Stenotrophomonas
KW - Stenotrophomonas maltophilia/drug effects
KW - Europe
KW - Humans
KW - Acinetobacter baumannii/drug effects
KW - Gram-Negative Bacteria/drug effects
KW - Anti-Bacterial Agents/pharmacology
KW - Cross Infection/drug therapy
KW - Drug Resistance, Multiple, Bacterial
KW - Immunocompromised Host
KW - Gram-Negative Bacterial Infections/drug therapy
KW - Pseudomonas aeruginosa/drug effects
UR - http://www.scopus.com/inward/record.url?scp=85062076432&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2019.01.005
DO - 10.1016/j.cmi.2019.01.005
M3 - Article
C2 - 30708122
AN - SCOPUS:85062076432
SN - 1198-743X
VL - 25
SP - 807
EP - 817
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 7
ER -